Valuation : Indivior PLC

Market Cap 4.12B 3.54B 3.33B 3.04B 5.7B 392B 5.74B 39.39B 15.32B 199B 15.45B 15.11B 657B P/E 2026 *
9.37x
P/E 2027 * 8.49x
Enterprise Value 4.1B 3.53B 3.32B 3.03B 5.68B 390B 5.73B 39.27B 15.27B 198B 15.4B 15.07B 655B EV / Sales 2026 *
3.08x
EV / Sales 2027 * 2.53x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-1.64% - - 4.12B
-1.52%-7.86%+57.90%+111.09% 1,047B
-0.82%-1.62%+50.05%+62.37% 646B
+0.37%-3.22%+21.87%+72.88% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.45%-0.27%+29.84%+91.34% 181B
Average -0.47%-2.68%+27.56%+48.48% 406.59B
Weighted average by Cap. -0.02%-3.46%+36.91%+64.88%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.08B 983M 1.84B 127B 1.86B 12.75B 4.96B 64.29B 5B 4.89B 213B 1.4B 1.2B 1.13B 1.03B 1.94B 133B 1.95B 13.4B 5.21B 67.55B 5.25B 5.14B 224B
Net income 474M 408M 383M 350M 657M 45.13B 662M 4.54B 1.77B 22.89B 1.78B 1.74B 75.76B 530M 456M 428M 391M 734M 50.43B 740M 5.07B 1.97B 25.58B 1.99B 1.95B 84.66B
Net Debt -12.5M -10.76M -10.1M -9.23M -17.31M -1.19B -17.44M -120M -46.53M -603M -46.93M -45.91M -2B -570M -491M -461M -421M -790M -54.24B -795M -5.46B -2.12B -27.51B -2.14B -2.09B -91.06B
Logo Indivior PLC
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-